Search
Returning search results with filters:
Remove filter for
Last updated: April 2022
Remove filter for
Last updated: 2022
Remove filter for
Type: Alert
Clear all
Type
Audience
Category
Issue
Last updated
Please note: using the search filters may not provide accurate search results for records prior to November 2021. When searching for older records, please ensure that you use the include archived checkbox.
Displaying 1 - 5 of 5 items.
UPDATE: April 21, 2022 – Pfizer recalls Accupril blood pressure tablets due to a nitrosamine impurity
Pfizer Canada ULC is recalling all lots of the prescription drug Accupril (quinapril hydrochloride) in 10 mg, 20 mg and 40 mg strengths due to the…
AlertPublic advisory | 2022-04-21
EVUSHELD (tixagevimab and cilgavimab for injection) was authorized by Health Canada on April 14, 2022. In order to provide rapid access to EVUSHELD in the context of the global COVID-19 pandemic, AstraZeneca will distribute product vials and cartons with…
AlertHealth professional risk communication | 2022-04-14
Sotrovimab, 500 mg IV, is unlikely to maintain efficacy against the Omicron BA.2 subvariant. Sotrovimab demonstrates reduced in vitro neutralization against the Omicron BA.2 subvariant.
Audience
Healthcare professionals responsible…
AlertHealth professional risk communication | 2022-04-14
Health Canada has updated its 2019 and 2017 safety reviews on breast implant-associated anaplastic large cell lymphoma (BIA-ALCL), a rare but serious cancer of the immune system that can develop next to a breast implant. This review found that there…
AlertPublic advisory | 2022-04-06
The product does not meet the flammability requirements for children’s sleepwear of the Children’s Sleepwear Regulations.
Loose-fitting children’s sleepwear can come in contact with flammable sources such as stove elements, candles, and matches more…
AlertPublic advisory | 2022-04-05